HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Waiting For Cannabidiol Guidance? US FDA Reminds Industry Of ‘Many Other Requirements’

Executive Summary

Two months after submitting CBD enforcement draft guidance for OMB review, FDA published separate draft guidance on studies for bioequivalents of an approved cannabidiol-based drug. But the draft guidance that the supplement industry awaits in pitched anticipation remains under review.

You may also be interested in...



Herbalife Adds Cannabinoid Skin Care Line On Top Of Reporting Record Quarterly Results

Direct seller announces both its third-quarter results and launch of Enrichual Hemp Relief Balm and Facial Serum formulated with broad-spectrum cannabinoids. Its $1.5bn net sales were led by 55.1% growth in the US and Canada to $398.7m.

Despite Hot Sales, US CBD Market’s Image Problem Cools Growth, Survey Suggests

US CBD consumers say scams and quality control are greatest concerns, and newer users are most concerned, according to a survey of 780 participants by Bigeye. Results also shed light on factors that could be keeping consumers from trying the products.

If Safety Data Open Door In US, Cannabinoids’ Lawful Use In Supplements At Least A Year Off

At FDLI annual meeting, attorneys cast doubt on CBD rules outlook. Paul Joseph says regulations are at least a year away while Jonathan Havens doubts FDA is even working on regulations, including GMPs, because it is still asking industry for specific safety details.

Related Content

Topics

UsernamePublicRestriction

Register

RS150491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel